BridgeMD
Compares treatment options for Liver Tumor; Surgery
Official title Stroke Volume Variation Versus Central Venous Pressure Guidance for Reducing Perioperative Blood Loss During Open Liver Resection
ClinicalTrials.gov ID: NCT06905015
What this study is testing
- What it's testing
- Liver resection is a major surgery that can be associated with significant intraoperative blood loss and blood transfusion. Among high-volume centers, median intraoperative blood loss ranges between 300-800 ml.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 20 to 70
You may be able to join if
- All genders, age 18 to 70 years old
- American Society of Anesthesiologists (ASA) physical status classification of I-III
- The patients who scheduled in elective open liver resection and diagnosed Hepatocellular Carcinoma, Cholangiocarcinoma, Liver metastasis, and Benign...
You likely can't join if
- Pregnancy
- Active cardiac conditions (unstable coronary syndromes, decompensated heart failure, significant arrhythmias, severe valvular disease, active...
- History of significant cerebrovascular disease (Patients with clinically significant stroke/CVA within 6 months prior surgery, severe carotid...
- Renal dysfunction (GFR \< 60 ml/min/1.73 m²)
- Abnormal coagulation parameters (INR \>1.5 not on warfarin and/or platelet count \<100,000)
- Preoperative autologous blood donation
See the full eligibility criteria
- All genders, age 18 to 70 years old
- American Society of Anesthesiologists (ASA) physical status classification of I-III
- The patients who scheduled in elective open liver resection and diagnosed Hepatocellular Carcinoma, Cholangiocarcinoma, Liver metastasis, and Benign malignant tumor.
- Pregnancy
- Active cardiac conditions (unstable coronary syndromes, decompensated heart failure, significant arrhythmias, severe valvular disease, active coronary artery disease within 6 months prior surgery)
- History of significant cerebrovascular disease (Patients with clinically significant stroke/CVA within 6 months prior surgery, severe carotid stenosis)
- Renal dysfunction (GFR \< 60 ml/min/1.73 m²)
- Abnormal coagulation parameters (INR \>1.5 not on warfarin and/or platelet count \<100,000)
- Preoperative autologous blood donation
- Tumor size \> 10 cm.
- Previous liver resection Withdrawal criteria:
- Unresectable tumor
- Persistent intraoperative hypotension that cannot be corrected with vasopressors.
- Cardiac arrest during operation
- Low central venous pressure (CVP \ 13%) cannot be achieved before and during liver parenchymal transection.
The study team makes the final eligibility decision.
Where it's taking place
- Chiang Mai, Chiangmai, Thailand
Compensation & support
A stipend or compensation may be offered.
Compensation likely.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 20 years to 70 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Chiang Mai, Chiangmai, Thailand. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.